Towards personalized treatment in atopic dermatitis.

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Severe atopic dermatitis (AD) historically relied on oral immunosuppressants and topical treatments.
• Dupilumab, an IL-4 receptor alpha antibody, represents a significant advancement as the first available antibody therapy for AD.
• The therapeutic landscape for severe AD is rapidly evolving with upcoming antibody-based treatments and small molecules.

Purpose of the Study:

• To review current and emerging therapies for severe atopic dermatitis.
• To explore strategies for optimizing existing oral immunosuppressive treatments.
• To provide insights into the future of personalized medicine for AD management.

Main Methods:

• Literature review of current and future therapies for severe atopic dermatitis.
• Analysis of treatment optimization strategies for oral immunosuppressants.
• Exploration of the role of biomarkers in personalized AD treatment.

Main Results:

• The review covers established oral immunosuppressants and novel biologic agents like dupilumab.
• Future treatments include more antibody-based therapies and small molecules for severe AD.
• Biomarkers are essential for identifying patient subgroups likely to respond to targeted, expensive new treatments.

Conclusions:

• Personalized treatment approaches, guided by biomarkers, are critical for managing heterogeneous AD.
• Pharmacogenomic biomarkers can enhance the efficacy of current oral immunosuppressants for moderate to severe AD.
• A combination of optimized existing therapies and novel targeted treatments will shape future AD management.